Member Info for liquid1

They had a couple of bad years because of Covid!

Revenue is 1 billion pounds!

FFS! The banks are not stupid and give MCLS their funding, Covid is now something we live with and lockdowns are gone!

400k on the bid and 30k on the ask!

Wants to rocket!

As previously stated, the Group continues to believe that a financing solution will be found that involves its existing partners and stakeholders. However, there are also other options available to it. The Group confirms that it recently received an approach for the whole business, which has subsequently been withdrawn and there are no further discussions with that party or any other party in relation to an offer for the whole business. In addition, the Group has also received indications of interest for parts of the business. The Board will consider all options with the aim of maximising value for all stakeholders.

Timing of FY21 full year results

The Group is in the process of finalising its full year results, but now expects to publish in May 2022 to allow additional time for banking discussions to conclude.

4p close??

Mcap gotta be more than 57m

Group order intake during FY22 was GBP223.7m. This represents a year-on-year increase of 31.6% on a reported basis and 35.6% at constant exchange rates. Excluding the recently announced GBP11.0m long term military contract, order intake for the period increased by 25.2% or 29.2% at constant exchange rates. The current order book of GBP84.1m is a record high for the Group (31 March 2021: GBP53.6m).

Portfolio of Assets

There are 6 key parts of Immupharma:
1. Lupuzor – Lupus (Sales Potential >$1bn per annum) Preparing to Commence Phase 3 lupus trial end 2020 / beginning 2021, with SPA application before FDA with decision imminent. Partnered with Avion who are funding the Phase 3 trial. Up to 17% US royalties, with IMM retaining 100% European and ROW rights.

2. Lupuzor (P140) – CIPD (SP >$500m per annum), aim to move into a proof of concept study. Also there is preclinical research to show that many other autoimmune diseases can be targeted including Rheumatoid Arthritis, Mixed Connective Tissue Disease, Sjogren's Syndrome, Multiple Sclerosis, Insulin Dependent Diabetes, Crohn's Disease and Bullous Diseases.

3. Metabolism – New Bioglucagon (SP $500m per annum), bio equivalence study 2021, potential launch 2022

4. Anti Infectives – New BioAMP-B (SP $400m per annum), bio equivalence study 2021, potential launch 2022

5. Nucant Cancer Programme – Phase I/IIa trial of reformulation completed 2015. The intention is to pre-treat with Nucant and then deliver the standard dose of cytotoxic drug, Gemcitabin for example in pancreatic cancer. Discussions to partner with Incanthera broke down in 2019, new partner now sought.

6. 11.9% share in Incanthera with options to buy the same number of shares again, which has a lead product Sol, a formulation designed to deliver into the skin an active ingredient known to prevent the conversion of solar keratoses into skin cancer. Confirmation announced in 2020 of exceeding bioequivalence compared with oral delivery and with statistically significant greater dermal delivery compared with four known comparator products

Low free float

Shares outstanding 284.98m
Free float 139.34m

https://markets.ft.com/data/equities/tearsheet/summary?s=IMM:LSE

Yes

Mcap is way too cheap

ImmuPharma Says Lupus Treatment Study Met Key FDA Endpoints

Source: Dow Jones News
By Anthony O. Goriainoff


ImmuPharma PLC said Wednesday that its lupus treatment Lupuzor/P140 met the required key endpoints in the pharmacokinetic study requested by the U.S. Food & Drug Administration.

The London-listed drug company said that in line with all human dosing to date, Lupuzor was safe and well tolerated across all doses and in all subjects.

The company, which focuses on autoimmune diseases, metabolic diseases, anti-infectives and cancer, said the data was part of the new Phase 3 trial of Lupuzor in lupus patients.

A pharmacokinetic study times the course of a drug's movement into, through, and out of the body and studies how the body affects a drug.

ImmuPharma said the data opened the way for the start of all clinical studies within the P140 platform, and that in addition to lupus it also planned to conduct a Phase 2a/3 trial in chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune disorder.

"This is a significant milestone for ImmuPharma and for shareholders, and recognition of the key investment thesis behind ImmuPharma, in respect to having P140 (Lupuzor), a late-stage Phase 3 clinical asset for the treatment of lupus patients with a Phase 2a/3 pivotal trial in CIDP close behind," Chief Executive Tim McCarthy said.


Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com


(END) Dow Jones Newswires

Blockbuster potential’

Northland Capital Partners analyst Vadim Alexandre believes the shares are grossly undervalued. He has a target price of 171p, which is more than three times ImmuPharma’s current share price of 50.7p.

Vadim says: ‘The drug has been looked upon favourably by US regulators, which have deemed it a priority treatment.

‘Should the drug be approved, we estimate it could achieve multi-billion dollar annual sales.’

It is important to highlight that despite its side-effects, GSK’s Benlysta reached sales of over $400m in 2015 with annual sales predicted to hit $1bn by 2020.

Lupuzor has demonstrated it is safer and more effective than Benlysta in its Phase IIb trial, and may benefit from higher uptake by lupus sufferers if it is approved.

Management anticipates that Lupuzor will also be cheaper than its competitor, which is currently priced at around $30,000 annually per person.

https://www.sharesmagazine.co.uk/article/why-lupus-treatment-is-a-potential-game-changer

https://www.proactiveinvestors.co.uk/companies/news/979630/immupharma-drug-clears-a-significant-hurdle-979630.html

mmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive, Tim McCarthy, described as a ‘significant milestone’ the successful completion of a pharmacokinetic (PK) study of its lead asset Lupuzor, also known as P140.

PK studies are there to assess how the body absorbs, distributes, metabolises, and excretes a compound.

In ImmuPharma’s case, the evaluation was mandated by the US Food & Drug Administration as part of the regulatory sign-off process

These were 144p before end point not achieved

www.kefi-minerals.com/files/files/Orior-Capital-KEFI-The-brakes-are-off-April22a.pdf

KEFI looks incredibly undervalued: Valuing Tulu Kapi as a development stage asset at US$1,000/oz of attributable planned production, and Hawiah and Jibal Qutman on attributable resources at US$60/oz gold or gold-equivalent (AuEq), both in line with peers, suggests a current valuation for KEFI of 4.8p/share. This is 6x the current share price.

KEFI has an estimated NPV of 12.9p/share, based on the attributable values of the three projects, and a gold price of US$1,830/oz. A portfolio of six other companies with gold development projects in Africa, and with similar gold price assumptions, currently trades at 43% of NPV. Valuing KEFI in line with peers would suggest a valuation of 5.5p/share. The market is currently KEFI at just 6% of NPV. On this basis, KEFI is arguably one of the most undervalued gold developers, anywhere

What’s not factored in?
Additional mineralisation at Tulu Kapi underground:

there may be scope to lower the cut-off grade
and bring additional material into the mine plan

www.kefi-minerals.com/files/files/Orior-Capital-KEFI-The-brakes-are-off-April22a.pdf

KEFI looks incredibly undervalued: Valuing Tulu Kapi as a development stage asset at US$1,000/oz of attributable planned production, and Hawiah and Jibal Qutman on attributable resources at US$60/oz gold or gold-equivalent (AuEq), both in line with peers, suggests a current valuation for KEFI of 4.8p/share. This is 6x the current share price.

KEFI has an estimated NPV of 12.9p/share, based on the attributable values of the three projects, and a gold price of US$1,830/oz. A portfolio of six other companies with gold development projects in Africa, and with similar gold price assumptions, currently trades at 43% of NPV. Valuing KEFI in line with peers would suggest a valuation of 5.5p/share. The market is currently KEFI at just 6% of NPV. On this basis, KEFI is arguably one of the most undervalued gold developers, anywhere

What’s not factored in?
Additional mineralisation at Tulu Kapi underground:

there may be scope to lower the cut-off grade
and bring additional material into the mine plan

McColl’s has been locked in talks with banks since February in a bid to secure its future survival following months of tough trading, with a number of profit warnings issued as the chain battled availability and supply issues, as well as lower footfall.

The Issa brothers are understood to have held talks to buy the business but later backed out, while wholesale supplier Morrisons is reported to be watching the situation closely.

https://www.thegrocer.co.uk/finance/mccolls-shares-surge-70-higher-as-c-store-chain-remains-locked-in-talks-with-lenders/666392.article

Maybe weekend news in the press??

Not long to go!

3 weeks to MAY

The Group is in the process of finalising its full year results, but now expects to publish in May 2022 to allow additional time for banking discussions to conclude

Yes speeding ticket cannot be re-issued.

Market knows news coming!

Outlook

As previously stated, the Group continues to believe that a financing solution will be found that involves its existing partners and stakeholders. However, there are also other options available to it. The Group confirms that it recently received an approach for the whole business, which has subsequently been withdrawn and there are no further discussions with that party or any other party in relation to an offer for the whole business. In addition, the Group has also received indications of interest for parts of the business. The Board will consider all options with the aim of maximising value for all stakeholders.

7 April 2022

McColl's Retail Group plc

("McColl's" or the "Group")

Statement re share price movement

McColls's notes the recent rise in the Company's share price and confirms that it does not know of any reason for this price movement.

As previously announced, the Group remains in ongoing dialogue with its lenders with a view to achieving a longer-term agreement in relation to the balance of its existing facility, however, there is no certainty as to the successful outcome of these discussions.

A further update will be made as and when these discussions conclude.